Synthetic biology company Intrexon celebrate their IPO at the New York Stock Exchange on August 8, 2013 in New York City.
Description
Intrexon Corporation is engaged in the business of synthetic biology. Using the Company’s suite of complementary technologies, it design, build and regulate gene programs, or sequences of deoxyribonucleic acid (DNA) that control cellular function, and cellular systems, or activities that take place within a cell and the interaction of those systems in the greater cellular environment, to enable the development of new and improved products and manufacturing processes across a variety of end markets, including healthcare, food, energy and environmental sciences. Its technologies include the UltraVector gene design and fabrication platform; Cell Systems Informatics; LEAP-cell identification and selection, and mAbLogix-antibody discovery. The Company’s LEAP technology facilitates the automated identification of an individual cell with the highest levels of expression, quality and potency from a population of over 100,000 cells.
Address
20374 Seneca Meadows Parkway
GERMANTOWN, MD 20876
GERMANTOWN, MD 20876
Key stats and ratios
| Q3 (Sep '13) | 2012 | |
| Net profit margin | 244.43% | -586.00% |
| Operating margin | -196.27% | -539.73% |
| EBITD margin | - | -482.39% |
| Return on average assets | 15.87% | -61.24% |
| Return on average equity | 6758.35% | - |
| Employees | 148 |
No comments:
Post a Comment